Day: March 29, 2022

ACTON, Mass., March 29, 2022 (GLOBE NEWSWIRE) — Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, announced today fourth quarter and full year financial results for the period ended December 31, 2021. The Company’s revenue for the year ended December 31, 2021, was $24.9 million versus $21.4 million for the year ended December 31, 2020, an increase of 17%. Net loss for the year ended December 31, 2021, was $0.7 million or $0.12 per diluted share, versus net loss of $3.9 million or $0.70 per diluted share, for the comparable period last year. The Company’s revenue for the quarter ended December 31, 2021, was $6.4 million versus $5.3 million for the quarter ended December 31, 2020, an increase of 21%. Net loss for the quarter ended December 31, 2021, was $1.6 million or $0.29...

SAB executing on its strategy to build a proprietary immune and autoimmune disorders pipeline, including respiratory diseases that affect immunocompromised patients Plans to announce full data from Phase 2a trial that evaluated SAB-176 for the treatment of seasonal influenza mid-2022 – first full clinical data set from DiversitAb platform SAB continues to advance on Rapid Response Antibody Program collaboration with US Department of Defense Generated robust data set, demonstrated proof-of-concept and validated platform through accelerated clinical development of SAB-185, a high-potency fully-human polyclonal therapeutic, to address pandemic need for novel treatments against emerging biothreats, respiratory viruses and viral mutations Sufficient cash and government funding anticipated to operate through third quarter 2023 SIOUX FALLS,...

Alan Bash, experienced biopharmaceutical executive, appointed President and CEO Clinical trials with vidutolimod (CMP-001) in melanoma, head and neck cancer indications ongoing; Trial dosing initiated in cohorts for PD-1 refractory non-melanoma skin cancers Preliminary clinical data readouts anticipated in second half of 2022 CAMBRIDGE, Mass., March 29, 2022 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced full year 2021 financial results and provided a business update. “Our vidutolimod program continued to advance in 2021 and expand into multiple cancer indications,” said Alan Bash, President and Chief Executive Officer of Checkmate....

NEWARK, Calif., March 29, 2022 (GLOBE NEWSWIRE) — Concentrix Corporation (NASDAQ: CNXC), a leading global provider of customer experience (CX) solutions and technology, today announced financial results for the fiscal first quarter ended February 28, 2022.  Three Months Ended      February 28, 2022   February 28, 2021   ChangeRevenue($M) $ 1,536.1     $ 1,353.3     13.5 %Operating income($M) $ 147.7     $ 134.9     9.5 %Non-GAAP operating income($M)(1) $ 201.9     $ 176.6     14.3 %Operating margin   9.6 %     10.0 %   -40 bpsNon-GAAP operating margin(1)   13.1 %     13.1 %   0 bpsNet income($M) $ 110.3     $ 88.8     24.2 %Non-GAAP net income($M)(1) $ 150.7     $ 120.0     25.6 %Adjusted EBITDA($M)(1) $ 237.9     $ 212.6     11.9 %Adjusted EBITDA margin(1)   15.5 %     15.7 %   -20 bpsDiluted...

Revenue and Earnings Per Share Exceed Guidance Ranges Full Year Guidance Increased for Revenue and Earnings Per Share BEDFORD, Mass., March 29, 2022 (GLOBE NEWSWIRE) — Progress (Nasdaq: PRGS), the trusted provider of infrastructure software, today announced financial results for its fiscal first quarter ended February 28, 2022. First Quarter 2022 Highlights:Revenue of $144.9 million increased 19% year-over-year on an actual currency basis, and 21% on a constant currency basis. Non-GAAP revenue of $147.5 million increased 12% on an actual currency basis, and 14% on a constant currency basis. Annualized Recurring Revenue (ARR) of $479 million increased 12% year-over-year on a constant currency basis. Operating margin was 20% and Non-GAAP operating margin was 40%. Diluted earnings per share was $0.46 compared to $0.42 in the same...

Fourth quarter 2021 revenue of $23.0 million contributed to record full year revenue of $81.6 million, 46% growth over the prior year Established over 75 new customer accounts, expanding and diversifying revenue base Substantial cash and investments of $657.7 million at year-end Maintaining 2022 full year revenue guidance of $105-110 million Management to host conference call today at 4:30pm ETBOULDER, Colo., March 29, 2022 (GLOBE NEWSWIRE) — SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter and year ended December 31, 2021. “2021 was a transformational year for SomaLogic, and we see a long runway to continue executing on our growth plan ahead,” said Roy Smythe, M.D., SomaLogic’s Chief Executive Officer. “Twenty years of research and innovation have culminated...